Suppression of NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone

Chemico-Biological Interactions

Volumn 188, Issue 1, 2010, Pages 75-85

  Ban, Jung Ok ^a   Kwak, Dong Hoon ^a   Oh, Ju Hoon ^a   Park, Eun Jung ^a   Cho, Min Chul ^a   Song, Ho Seub ^b   Song, Min Jong ^c   Han, Sang Bae ^a   Moon, Dong Cheul ^a   Kang, Keon Wook ^d   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Chosun University   (South Korea)

Author keywords

Apoptosis; Colon cancer; GSK 3 ; NF B; Troglitazone

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CHROMAN DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; CELL CYCLE; CELL DIVISION; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; PATHOLOGY;

CELL CYCLE; CELL DIVISION; CHROMANS; COLONIC NEOPLASMS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NF-KAPPA B; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 77956172120     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.06.001     Document Type: Article

References (41)

1. Zhang X.Y., Chen L.H., Guan Y.F. PPAR family and its relationship to metabolic syndrome. Sheng Li Ke Xue Jin Zhan 2005, 36:6-12.
2. Shimada T., Kojima K., Yoshiura K., Hiraishi H., Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002, 50:658-664.
3. Han S., Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?. Anticancer Drugs 2007, 18:237-244.
4. Qiao L., Dai Y., Gu Q., Chan K.W., Ma J., Lan H.Y., Zou B., Rocken C., Ebert M.P., Wong B.C. Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2. Cancer Lett. 2008, 268:260-271.
5. Yang Y.C., Tsao Y.P., Ho T.C., Choung I.P. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int. J. Gynecol. Cancer 2007, 17:418-425.
6. Yamauchi A., Takahashi I., Takasawa S., Nata K., Noguchi N., Ikeda T., Yoshikawa T., Shervani N.J., Suzuki I., Uruno A., Unno M., Okamoto H., Sugawara A. Thiazolidinediones inhibit REG Ialpha gene transcription in gastrointestinal cancer cells. Biochem. Biophys. Res. Commun. 2009, 379:743-748.
7. Smith A.G., Beaumont K.A., Smit D.J., Thurber A.E., Cook A.L., Boyle G.M., Parsons P.G., Sturm R.A., Muscat G.E. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells. Int. J. Biochem. Cell Biol. 2009, 41:844-852.
8. Coimbra R., Melbostad H., Loomis W., Porcides R.D., Wolf P., Tobar M., Hoyt D.B. LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression. J. Trauma 2006, 60:115-125.
9. Mattson M.P., Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006, 13:852-860.
10. Suh J, Rabson A.B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J. Cell Biochem. 2004, 2004:100-117.
11. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
12. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
13. Garg A., Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16:1053-1068.
14. Lee S.Y., Cho J.S., Yuk D.Y., Moon D.C., Jung J.K., Yoo H.S., Lee Y.M., Han S.B., Oh K.W., Hong J.T. Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. J. Pharmacol. Sci. 2009, 111:124-136.
15. Lind D.S., Hochwald S.N., Malaty J., Rekkas S., Hebig P., Mishra G., Moldawer L.L., Copeland E.M., Mackay S. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 2001, 130:363-369.
16. Dong Q.G., Sclabas G.M., Fujioka S., Schmidt C., Peng B., Wu T., Tsao M.S., Evans D.B., Abbruzzese J.L., McDonnell T.J., Chiao P.J. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002, 21:6510-6519.
17. Zhang H., Morisaki T., Nakahara C., Matsunaga H., Sato N., Nagumo F., Tadano J., Katano M. PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 2003, 22:2088-2096.
18. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 2001, 107:241-246.
19. Suh J., Rabson A.B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J. Cell Biochem. 2004, 91:100-117.
20. Bren-Mattison Y., Meyer A.M., Van Putten V., Li H., Kuhn K., Stearman R., Weiser-Evans M., Winn R.A., Heasley L.E., Nemenoff R.A. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol. Pharmacol. 2008, 73:709-717.
21. Wang L.H., Yang X.Y., Zhang X., Farrar W.L. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood 2007, 110:4373-4384.
22. Takahashi-Yanaga F., Sasaguri T. Drug development targeting the glycogen synthase kinase-3beta(GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J. Pharmacol. Sci. 2009, 109:179-183.
23. Song S., Mazurek N., Liu C., Sun Y., Ding Q.Q., Liu K., Hung M.C., Bresalier R.S. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009, 69:1343-1349.
24. Wang Q., Zhou Y., Wang X., Evers B.M. p27 Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells. Cell Death Differ. 2008, 15:908-919.
25. Yang M., Zhong W.W., Srivastava N., Slavin A., Yang J., Hoey T., An S. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:6027-6032.
26. Buss H., Dörrie A., Schmitz M.L., Frank R., Livingstone M., Resch K., Kracht M. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J. Biol. Chem. 2004, 279:49571-49574.
27. Deng J., Xia W., Miller S.A., Wen Y., Wang H.Y., Hung M.C. Crossregulation of NF-kappaB by the APC/GSK-3beta/beta-catenin pathway. Mol. Carcinog. 2004, 39:139-146.
28. Ougolkov A.V., Bone N.D., Fernandez-Zapico M.E., Kay N.E., Billadeau D.D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110:735-742.
29. Min H.J., Koh S.S., Cho I.R., Srisuttee R., Park E.H., Jhun B.H., Kim Y.G., Oh S., Kwak J.E., Johnston R.N., Chung Y.H. Inhibition of GSK-3beta enhances reovirus-induced apoptosis in colon cancer cells. Int. J. Oncol. 2009, 35:617-624.
30. Bilim V., Ougolkov A., Yuuki K., Naito S., Kawazoe H., Muto A., Oya M., Billadeau D., Motoyama T., Tomita Y. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br. J. Cancer 2009, 101:2005-2014.
31. Ban J.O., Oh J.H., Hwang B.Y., Moon D.C., Jeong H.S., Lee S., Kim S., Lee H., Kim K.B., Han S.B., Hong J.T. Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-kappaB activity via direct interaction with p50. Mol. Cancer Ther. 2009, 8:1613-1624.
32. Thompson E.A. PPARgamma physiology and pathology in gastrointestinal epithelial cells. Mol. Cells 2007, 24:167-176.
33. Theocharis S., Giaginis C., Parasi A., Margeli A., Kakisis J., Agapitos E., Kouraklis G. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival, Dig. Dis. Sci. 2007, 52:2305-2311.
34. Piva R., Gianferretti P., Ciucci A., Taulli R., Belardo G., Santoro M.G. 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood 2005, 105:1750-1758.
35. Schlezinger J.J., Jensen B.A., Mann K.K., Ryu H.Y., Sherr D.H. Peroxisome proliferator-activated receptor gamma-mediated NF-kappa B activation and apoptosis in pre-B cells. J. Immunol. 2005, 169:6831-6841.
36. Setoguchi K., Misaki Y., Terauchi Y., Yamauchi T., Kawahata K., Kadowaki T., Yamamoto K. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J. Clin. Invest. 2001, 108:1667-1675.
37. Ougolkov A.V., Fernandez-Zapico M.E., Bilim V.N., Smyrk T.C., Chari S.T., Billadeau D.D. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 2006, 12:5074-5081.
38. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urrutia R.A., Billadeau D.D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65:2076-2081.
39. Bournat J.C., Brown A.M., Soler A.P. Wnt-1 dependent activation of the survival factor NF-kappaB in PC12 cells. J. Neurosci. Res. 2000, 61:21-32.
40. Pap M., Cooper G.M. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway. Mol. Cell Biol. 2002, 22:578-865.
41. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406:86-90.